Sun Pharma gets U.S. FDA nod for Prevacid generic drug
MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd (SUN.NS) said its unit has received U.S. Food and Drug Administration's (USFDA) final approval for the generic version of Prevacid.
The approval is for Lansoprazole Delayed-Release Capsules USP, 15 and 30 mg, which are therapeutic equivalents of Takeda Pharmaceutical Co. Ltd's capsules, the company said in a release late on Saturday.
The capsules have annual sales of $430 million in the United Sates, it said.
The capsules are used for short-term treatment for healing and symptom relief of active duodenal ulcer, it said.
(Reporting by Subhadip Sircar; Editing by Robert Birsel)
- Tweet this
- Share this
- Digg this
Trending On Reuters
India's main public health programmes, aimed at millions of rural poor, have been in disarray for months because the government changed the way that over $1.3 billion in funds were distributed, according to data and letters seen by Reuters. Full Article | Graphic: India's health funding